 In our current study in Hodgkins lymphoma, we are giving these higher doses of ICE called augmented ICE to patients who also have higher risk. We hope to show in this study that by using Rituximab and augmented ICE that we can improve your ability to achieve a remission that is, to have the disease go away. 